Evogene
EVGN
17 hedge funds and large institutions have $12M invested in Evogene in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
11% more capital invested
Capital invested by funds: $10.8M → $12M (+$1.23M)
6% more funds holding
Funds holding: 16 → 17 (+1)
0.22% more ownership
Funds ownership: 2.62% → 2.84% (+0.22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$813K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$39.8K |
| 3 |
Goldman Sachs
New York
|
+$37.2K |
| 4 |
Jane Street
New York
|
+$26.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$23.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Moon Capital Management
New York
|
-$117K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$18.7K |
| 3 |
Citigroup
New York
|
-$12K |
EVGN Hedge Fund Activity: Q1 2020 in Review
17 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2020, worth a combined $12M — up 11% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EVGN positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Clal Insurance, adding an estimated $813K. The largest seller was Moon Capital Management, cutting an estimated $117K.
- 17 institutional investors held Evogene (EVGN) as of Q1 2020, up from 16 in Q4 2019.
- Funds reported $12M of Evogene stock for Q1 2020, up 11% quarter-over-quarter.
- 2 funds opened new Evogene positions in Q1 2020 and 1 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q1 2020 was Clal Insurance, an estimated $813K added.
- The largest Evogene seller in Q1 2020 was Moon Capital Management, an estimated $117K sold.
Based on aggregated 13F filings for Q1 2020.